PxRadia Inc. is developing a mAb that directly targets ceramide molecules in the cell membrane, blocking their ability to induce apoptosis in tissues subjected to stressors such as radiation. But the mAb doesn't impair normal ceramide synthesis or metabolism, meaning it may be safer than other ceramide-targeting compounds in development.

The company is pursuing gastrointestinal acute radiation syndrome (GI ARS), but also sees applications for preventing stem cell death in cytolytic T cell-mediated autoimmune diseases like graft-versus-host disease (GvHD).